Terapia radiorecettoriale dei tumori neuroendocrini pancreatici
Rassegna
First Online:
- 92 Downloads
Sommario
La terapia radiorecettoriale con 177Lu-DOTATATE (Lu-PRRT) è una valida opzione di terapia mirata nei tumori neuroendocrini pancreatici G1–G2 (pNET). È una terapia efficace in oltre l’80% dei casi. Complessivamente è ben tollerata, con tossicità midollare e renale lieve e reversibile, in particolare con frazionamento della dose totale di radiofarmaco. Nella gestione dei pazienti pNET, la PET con FDG è un importante fattore prognostico legato al metabolismo glucidico tumorale.
Parole chiave
177Lu-DOTATATE Tumori neuroendocrini P-NET PRRT Analogo della somatostatina Terapia mirata FDG-PETNotes
Conflitto di interesse
Gli autori Silvia Nicolini, Maddalena Sansovini, Stefano Severi, Manuela Monti, Annarita Ianniello, Federica Matteucci e Giovanni Paganelli dichiarano di non avere conflitti di interesse.
Consenso informato
Lo studio presentato in questo articolo non ha richiesto sperimentazione umana.
Studi sugli animali
Gli autori di questo articolo non hanno eseguito studi sugli animali.
Supplementary material
Bibliografia
- 1.Lawrence B, Gustafsson BI, Chan A et al. (2011) The epidemiology of gastroenteropancreatic neuroendocrine tumors. Endocrinol Metab Clin N Am 40:1–18 CrossRefGoogle Scholar
- 2.Klimstra DS, Modlin IR, Coppola D et al. (2010) The pathologic classification of neuroendocrine tumors: a review of nomenclature, grading, and staging systems. Pancreas 39(6):707 CrossRefPubMedGoogle Scholar
- 3.Rindi G, Arnold R, Bosman FT et al. (2010) Nomenclature and classification of neuroendocrine neoplasms of the digestive system. In: Bosman FT, Carneiro F, Hruban RH, Theise ND (eds) WHO classification of tumours of the digestive system. IARC Press, Lyon, pp 13–14 Google Scholar
- 4.Akerström G, Falconi M, Kianmanesh R et al. (the Mallorca Consensus Conference participants; European Neuroendocrine Tumor Society) (2009) ENETS consensus guidelines for the standards of care in neuroendocrine tumors: pre- and perioperative therapy in patients with neuroendocrine tumors. Neuroendocrinology 90(2):203–208 CrossRefPubMedGoogle Scholar
- 5.Bodei L, Cremonesi M, Grana C et al. (2004) Receptor radionuclide therapy with 90Y-[DOTA]0-Tyr3-octreotide (90Y-DOTATOC) in neuroendocrine tumours. Eur J Nucl Med Mol Imaging 31(7):1038–1046 CrossRefPubMedGoogle Scholar
- 6.Bodei L, Cremonesi M, Ferrari M et al. (2008) Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with (90)Y-DOTATOC and (177)Lu-DOTATATE: the role of associated risk factors. Eur J Nucl Med Mol Imaging 35(10):1928 CrossRefGoogle Scholar
- 7.Ngo DC, Ververis K, Tortorella SM et al. (2015) Introduction to the molecular basis of cancer metabolism and the Warburg effect. Mol Biol Rep 42(4):819–823 CrossRefPubMedGoogle Scholar
- 8.Binderup T, Knigge U, Loft A et al. (2010) 18F-fluorodeoxyglucose positron emission tomography predicts survival of patients with neuroendocrine tumors. Clin Cancer Res 16(3):978–985 CrossRefPubMedGoogle Scholar
- 9.Severi S, Nanni O, Bodei L et al. (2013) Role of 18FDG PET/CT in patients treated with 177Lu-DOTATATE for advanced differentiated neuroendocrine tumours. Eur J Nucl Med Mol Imaging 40(6):881–888 CrossRefPubMedGoogle Scholar
- 10.Kwekkeboom DJ, de Herder WW, Kam BL et al. (2008) Treatment with radiolabeled somatostatin analog [177Lu-DOTA0, Tyr3]ocreotate: toxicity, efficacy and survival. J Clin Oncol 26(13):2124–2130 CrossRefPubMedGoogle Scholar
- 11.Yao JC, Shah MH, Ito T et al. (the RAD001 in Advanced Neuroendocrine Tumors, Third Trial (RADIANT-3) Study Group) (2011) Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 364(6):514–523 CrossRefPubMedPubMedCentralGoogle Scholar
- 12.Paganelli G, Sansovini M, Ambrosetti A et al. (2014) 177 Lu-Dota-octreotate radionuclide therapy of advanced gastrointestinal neuroendocrine tumors: results from a phase II study. Eur J Nucl Med Mol Imaging 41(10):1845–1851 CrossRefPubMedGoogle Scholar
- 13.Rindi G, Wiedemann B (2012) Neuroendocrine neoplasms of the gut and pancreas: new insights. Nat Rev Endocrinol 8:54–64 CrossRefGoogle Scholar
Copyright information
© Springer International Publishing AG 2016